Search clinical trials for: Indolent B-Cell Lymphomas

Total 2132 results

Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children...

Recruiting

Multi-CAR-T Cells Targeting B Cell Lymphomas

B Cell Lymphoma (BCL)

China
Zhejiang DTRM Biopharma

Recruiting

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter's Transformation | Relapsed Chronic Lymphocytic Leukemia

United States
Huiqiang Huang

Recruiting

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma (RIPPLE)

Lymphoma, B-Cell

China
University Hospital, Limoges

Recruiting

Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas (ExoReBLy)

Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)

France
BioInvent International AB

Recruiting

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma

Spain, United States, Brazil, Sweden, Germany, Poland
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Recruiting

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Waldenstrom... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Double-Expressor Lymphoma | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise... and other conditions

United States
Fred Hutchinson Cancer Center
Mustang Bio

Active, not recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
Bayer

Active, not recruiting

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-3)

Lymphoma,Non-Hodgkin

China, Hong Kong, Spain, Taiwan, Turkey, Japan, Russian Federation, Singapore, France, Austria, Bulgaria, Korea, Republic of, Malaysia, Thailand, United States, Hungary, Italy, Poland, Portugal, Germany, Mexico, Romania, Australia, Uk... and more
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma | Ann... and other conditions

United States
Pfizer

Terminated

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Solid Tumor | Hematologic Malignancies

United States, Canada
Hoffmann-La Roche

Active, not recruiting

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Non-Hodgkin Lymphoma | B-Cell Lymphoma

United States, Italy, Canada, Australia, Spain, Denmark, France, Germany, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma | Chronic Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Anaplastic Large Cell Lymphoma and other conditions

United States
Celldex Therapeutics
Merck Sharp & Dohme LLC

Completed

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Melanoma | Follicular Lymphoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Pancreatic Adenocarcinoma | Ovarian Cancer | Fallopian Tube Cancer | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | ... and other conditions

United States
Michael A. Thompson, MD, PhD
Vince Lombardi Cancer Clinic

Withdrawn

B-Cell Hematologic Malignancy Vaccination Registry (HMvax-Regist)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Waldenstrom Macroglobulinemia | Monoclonal Gammopathy of Undetermined Significance | Hematological Malignancies | B-Cell Chronic Lymphocytic Leukemia | Lymphocytosis

United States
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Stingthera, Inc.
Merck Sharp & Dohme LLC

Terminated

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Advanced Solid Tumor | Advanced Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Indolent Non Follicular Lymphomas Prognostic Project

Indolent B-Cell Lymphomas

France, Italy, Brazil, Austria, Portugal, Ukraine
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

Lymphoma, Non-Hodgkin

United States, Italy, Austria, Canada, France, Germany, Japan, Spain, Sweden, United Kingdom
Ronald Levy
National Cancer Institute (NCI)

Active, not recruiting

TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | B-Cell Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Celgene

Completed

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)

Lymphoma, Non-Hodgkin

United States, Belgium, Germany, Japan, Netherlands, France, Sweden, Italy, Spain, Switzerland, United Kingdom, Finland
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Mayo Clinic; University of Pennsylvania; University...

Active, not recruiting

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Aggressive | B-cell Non-Hodgkin Lymphoma

United States
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | Transformed Non-Hodgkin Lymphoma | Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage... and other conditions

United States
Genmab
AbbVie

Terminated

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

United States, Spain, Netherlands, Belgium, France, Denmark
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Takeda

Active, not recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Burkitt's Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Primary CNS Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Aggressive Non-Hodgkin... and other conditions

United States
Kyowa Kirin Co., Ltd.

Active, not recruiting

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

Indolent B-cell Non-Hodgkin's Lymphoma

Japan
University of Washington
Janssen Pharmaceuticals

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma

United States
Fate Therapeutics

Withdrawn

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Transformed Indolent Non-Hodgkin's Lymphoma
Bayer

Completed

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Lymphoma, Non-Hodgkin

Belgium, France, Spain, Hong Kong, Turkey, Russian Federation, Singapore, United States, Canada, Germany, Australia, New Zealand, Finland, Austria, United Kingdom, Bulgaria, Hungary, Italy, Israel, Korea, Republic of, Poland, Port... and more
University of Maryland, Baltimore
Gilead Sciences; University of Miami Sylvester Comprehensive Cancer Center

Active, not recruiting

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Follicular Lymphoma | B-cell Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Non Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Transformed Lymphoma | Indolent Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Leukemia

United States
University of Pennsylvania

Completed

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Intraocular Lymphoma | Small Intestine Lymphoma | Testicular Lymphoma | B-cell... and other conditions

United States
Kyowa Kirin Co., Ltd.

Active, not recruiting

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Japan
Abramson Cancer Center at Penn Medicine

Completed

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Marginal Zone B-Cell Lymphoma | MALT Lymphoma | Lymphoma of Mucosa-Associated Lymphoid Tissue

United States
The Lymphoma Academic Research Organisation

Completed

Detection and Characterization of Residual Masses in Lymphomas (ADAMANTIUS)

Hodgkin Lymphoma | B-Cell Lymphoma

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
Bayer

Completed

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Lymphoma Non-Hodgkin

Japan
The Lymphoma Academic Research Organisation

Completed

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa Associated Lymphoid Tissue

France
Masonic Cancer Center, University of Minnesota

Completed

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

Follicular Lymphoma | Multiple Myeloma | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Indolent B Cell Lymphoma | Primary Mediastinal Lymphoma

United States
National Cancer Institute (NCI)

Completed

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma

United States
Yazeed Sawalha

Withdrawn

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular... and other conditions
Brian Hill
The Cleveland Clinic

Terminated

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Lymphoma | B Cell Lymphoma

United States
M.D. Anderson Cancer Center
Biogen; CTI BioPharma

Completed

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

Lymphoma

United States
Weill Medical College of Cornell University
M.D. Anderson Cancer Center; Massachusetts General Hospital; Genentech, Inc.

Completed

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R)

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma

United States

Search clinical trials for: Indolent B-Cell Lymphomas

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations